Tianjin Bioco Biochemical Co., Ltd., a high-tech Sino-American joint venture company established in 1991, is registered at Tianjin Economy Development Area (TEDA). Bioco is one of the leading Chinese manufacturers of biochemical reagents and pharmaceutical ingredients. The company has been honored as an“Advanced-New Technological Enterprise”by the Science Commission of Tianjin Municipality. Our products are of excellent quality and with reasonable price, and have been favored by an increasing number of customers from both domestic and abroad. We have been collaborating with more and more domestic and overseas partners to develop a variety of new products for human health. The company is located on the scenic campus of Nankai University, one of the top research institutes in China. Based on the advanced technologies and scientific capabilities of Nankai University, and adjacent world-renowned research instates in the mega-metropolitan area of Tianjin and Beijing, Bioco has successfully developed a wide variety of high purity biochemicals, pharmaceutical ingredients and fine chemicals, and put them into mass production. Among which, TTX and PMSF have been honored as“New Product of State Grade”by the Ministries of State Science Commission, and General Bureau of Technology Inspection. Our off-campus satellite plants are strategically located in the city of Tianjin, and the provinces of Hebei and Shandong, which are all within 1-hour driving distance from the port of Tianjin and Tianjin airport. Most of our products have been exported abroad, and our customers usually receive their shipments within one week since ordering. At Bioco, we have been striving to meet the needs from our customers and we never stop exploring into innovative ideas. We have been investing heavily into research and development of new products according to the market and our customers’requirement. With experienced researchers staffing our research and development team and collaborators from overseas, Bioco is equipped with capability of generating platforms, with molecular diagnostic technology into high-throughput diagnostic kits for infectious diseases. Our long-term business goal is to link Western technology, financial resources, and management skills with the emerging biotech market in China.